Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.32 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.32 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29725175 | 1.00 | ACHE (0.43) | ACHETSHRRAB9ANPC1LMNA | |
| SCHEMBL31212632 | 0.91 | ACHE (0.37) | ACHETSHRRAB9ANPC1ALDH1A1 | |
| Acetic Acid SCHEMBL29025325 | 0.86 | HPGD (0.36) | ACHERAB9ANPC1LMNAALDH1A1 | |
| SCHEMBL19888150 | 0.83 | ACHE (0.44) | ACHETSHRRAB9ANPC1ALDH1A1 | |
| SCHEMBL31212631 | 0.82 | NPC1 (0.33) | ACHERAB9ANPC1 | |
| SCHEMBL30451957 | 0.81 | TRPA1 (0.39) | ACHETSHRRAB9ANPC1LMNA | |
| Trifluoromethanesulfonic Acid SCHEMBL29767878 | 0.80 | KCNH2 (0.40) | ACHEIDO1 | |
| SCHEMBL25419897 | 0.76 | ACHE (0.40) | ACHETSHRRAB9ANPC1ALDH1A1 | |
| SCHEMBL5157528 | 0.76 | SLC22A2 (0.56) | ACHERAB9ANPC1PABPC1SLC22A2 | |
| SCHEMBL23161472 | 0.75 | TDP1 (0.38) | ACHERAB9ALMNAALOX12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220193076-A1 | METHODS OF TREATING BREAST CANCER WITH TUCATINIB | SEAGEN INC (US) | 2022-06-23 | — | — | US | claimed |
| EP-3917533-A1 | METHODS OF TREATING BREAST CANCER WITH TUCATINIB | Seagen Inc. (US) | 2021-12-08 | — | — | EP | claimed |
| CN-113613656-A | Method of treating breast cancer with ceratinib | 西根股份有限公司 | 2021-11-05 | — | — | CN | claimed |
| WO-2020159822-A1 | METHODS OF TREATING BREAST CANCER WITH TUCATINIB | SEATTLE GENETICS, INC. (US) | 2020-08-06 | — | — | WO | claimed |
| CN-104974227-B | The amphiphilic film targeting alpha-helix polypeptide of cation and its application | 中国科学院苏州纳米技术与纳米仿生研究所 | 2019-04-23 | — | — | CN | claimed |
| CN-107529563-A | A kind of chemical copper activator and preparation method | 苏州天承化工有限公司 | 2018-01-02 | — | — | CN | claimed |
| US-20080132447-A1 | Method of Screening for a Carnitine Transporter Agonist or Antagonist and it Uses | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-06-05 | — | — | US | claimed |
| EP-1781817-A2 | METHOD OF SCREENING FOR A CARNITINE TRANSPORTER AGONIST OR ANTAGONIST AND ITS USES | Sanofi-Aventis Deutschland GmbH (DE) | 2007-05-09 | — | — | EP | claimed |
| WO-2006018259-A2 | METHOD OF SCREENING FOR A CARNITINE TRANSPORTER AGONIST OR ANTAGONIST AND ITS USES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-02-23 | — | — | WO | claimed |
| EP-1627922-A1 | Method of screening for a carnitine transporter agonist or antagonist and its uses | Sanofi-Aventis Deutschland GmbH (DE) | 2006-02-22 | — | — | EP | claimed |
| US-20220193076-A1 | METHODS OF TREATING BREAST CANCER WITH TUCATINIB | SEAGEN INC (US) | 2022-06-23 | — | — | US | disclosed |
| EP-3917533-A1 | METHODS OF TREATING BREAST CANCER WITH TUCATINIB | Seagen Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| CN-113613656-A | Method of treating breast cancer with ceratinib | 西根股份有限公司 | 2021-11-05 | — | — | CN | disclosed |
| EP-3046542-B1 | SYNERGISTIC LIPOSOMAL FORMULATION FOR THE TREATMENT OF CANCER | COUNCIL SCIENT IND RES (IN) | 2021-01-06 | — | — | EP | disclosed |
| WO-2020159822-A1 | METHODS OF TREATING BREAST CANCER WITH TUCATINIB | SEATTLE GENETICS, INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| EP-1418922-A1 | COMPOSITIONS COMPRISING NEGATIVELY CHARCHED PHOSPHOLIPIDS FOR TREATMENT AND/OR PREVENTION OF MACULAR DEGENERATION AND METHOD FOR ITS MANUFACTURE | Eidgenoessische Technische Hochschule Zuerich (CH) | 2004-05-19 | — | — | EP | disclosed |
| US-20030050283-A1 | Composition for the treatment and/or prevention of macular degeneration, method for its manufacture, and its use for treating the eye | LYNKEUS BIOTECH GMBH (DE) | 2003-03-13 | — | — | US | disclosed |
| WO-2003018028-A1 | COMPOSITIONS COMPRISING NEGATIVELY CHARCHED PHOSPHOLIPIDS FOR TREATMENT AND/OR PREVENTION OF MACULAR DEGENERATION AND METHOD FOR ITS MANUFACTURE | EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH (CH) | 2003-03-06 | — | — | WO | disclosed |
| EP-1220673-A2 | MORPHOLINOL DERIVATIVES FOR THE TREATMENT OF OBESITY | GLAXO GROUP LIMITED (GB) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001026641-A2 | MORPHOLINOL DERIVATIVES FOR THE TREATMENT OF OBESITY | GLAXO GROUP LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193076-A1 | METHODS OF TREATING BREAST CANCER WITH TUCATINIB | BRCA1, TTBK2, TTBK1 | ACHE 2350/4885TSHR 1533/4885RAB9A 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.